Masgoret Paula, Gomar Carmen, Tena Beatriz, Taurá Pilar, Ríos José, Coca Miquel
Department of Anesthesiology, Hospital Clinic, University of Barcelona Laboratory of Biostatistics and Epidemiology, Universitat Autonoma de Barcelona, Biostatistics and Data Management Platform, IDIBAPS, Hospital Clinic, Barcelona, Spain.
Medicine (Baltimore). 2017 Apr;96(15):e6624. doi: 10.1097/MD.0000000000006624.
Studies designed to assess persistent postoperative pain (PPP) incidence after hepatectomies are lacking. Our aim was to assess PPP incidence 6 months after hepatectomies with intravenous (IV) or epidural (EPI) analgesia containing ketamine.Prospective observational comparative study between 2 cohorts of patients submitted to hepatectomy. Patients received 1 of 2 analgesic regimes containing ketamine: EPI group or IV group. Visual analog scale (VAS), Neuropathic Pain Symptom Inventory (NPSI), Pain Catastrophizing Scale (PCS), and quantitative sensorial testing (QST: to determine area of hyperalgesia/allodynia) were assessed preoperatively and postoperatively at 2 h, 24 h, 7 days, 1 month, and 6 months. VAS ≥ 1 at 1 and 6 months was considered indicative of PPP and VAS > 3 was considered as not controlled pain. Side effects and complications were registered.Forty-four patients were included: 23 in EPI group and 21 in IV group. Patients in IV group were older and had more comorbidities. No patient presented VAS > 3 at 1 or 6 months. VAS ≥ 1 at 1 and 6 months was 36.4% and 22.7%, respectively. No differences in VAS, NPSI, or PCS were found between groups. Allodynia/hyperalgesia area did not differ between groups and was infrequent and slight. Pain pressure threshold in the wound vertical component was significantly higher in EPI group after 7 days. IV group showed more cognitive side effects.Incidence of PPP at 6 months after open hepatectomies with EPI or IV analgesia containing ketamine was lower than previously reported for other abdominal surgeries.Ketamine influence on low PPP incidence and hyperalgesia cannot be discarded.
目前缺乏旨在评估肝切除术后持续性疼痛(PPP)发生率的研究。我们的目的是评估接受含氯胺酮静脉(IV)或硬膜外(EPI)镇痛的肝切除术后6个月时的PPP发生率。
对两组接受肝切除术的患者进行前瞻性观察性比较研究。患者接受含氯胺酮的两种镇痛方案之一:EPI组或IV组。术前以及术后2小时、24小时、7天、1个月和6个月评估视觉模拟量表(VAS)、神经性疼痛症状量表(NPSI)、疼痛灾难化量表(PCS)以及定量感觉测试(QST:用于确定痛觉过敏/异常性疼痛区域)。1个月和6个月时VAS≥1被视为PPP的指征,VAS>3被视为疼痛未得到控制。记录副作用和并发症。
共纳入44例患者:EPI组23例,IV组21例。IV组患者年龄更大且合并症更多。在1个月或6个月时没有患者的VAS>3。1个月和6个月时VAS≥1的发生率分别为36.4%和22.7%。两组之间在VAS、NPSI或PCS方面未发现差异。两组之间痛觉过敏/异常性疼痛区域无差异,且不常见且轻微。7天后EPI组伤口垂直方向的疼痛压力阈值显著更高。IV组显示出更多的认知副作用。
接受含氯胺酮的EPI或IV镇痛的开放性肝切除术后6个月时的PPP发生率低于先前报道的其他腹部手术。不能排除氯胺酮对低PPP发生率和痛觉过敏的影响。